Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan, Facing Rising Health Care Costs, May Slash Generic Drug Prices

This article was originally published in PharmAsia News

Executive Summary

Japan may try to accelerate the increased usage of generic drugs by drastically reducing prices, part of an effort to slash skyrocketing health care costs at a time when the country’s public debt is reaching a record high.

You may also be interested in...



AstraZeneca Sees Growth Opportunities in Japan As Population Continues To Age

AstraZeneca KK’s young president Gabriel Baertschi is eying more partnerships for cardiovascular, oncology and respiratory therapies in Japan.

Kyowa Hakko Kirin, Ultragenyx To Develop Treatment For X-linked Hypophosphatemia

Kyowa Hakko Kirin is committed to expansion, and the deal with Ultragenyx for a first-in-class therapy of a rare bone disorder is small but establishes a clinical trial foothold overseas

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC083103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel